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F E A T U R E  C O M M E N T A R Y
Michael J. Allen and Marcel Jaspars
 “How inappropriate to call this planet Earth when it is quite 
clearly Ocean”
—Arthur C. Clarke
Introduction
he oceans are the Earth’s largest biome and represent a 
unique environment characterized by high ionic concentra-
tions, high pressures, and low as well as high temperatures. 
These conditions impose stringent selection criteria on 
organisms that inhabit the seas and have given rise to a plethora of 
phyletic diversity. Furthermore, since life began in the oceans around 
3.8 billion years ago and terrestrial colonization by microbes only 
occurred over a billion years later, the oceans contain some of the 
most ancient life forms in existence.1 
To place this into perspective, despite our human-centric obsession 
with land plant and land animal diversity, terrestrial colonization by 
plants is thought to have occurred only a half billion years ago.2 As a 
direct consequence of this, a survey of the Kingdom Animalia shows 
that 21 of the 33 phyla are unique to the oceans, and only one is 
exclusively terrestrial.3 Where both terrestrial and marine representa-
tives exist, the number of marine species is greater in most cases. Of 
this biodiversity, only 12 marine animal phyla have been assessed 
for any biotechnological application, with the Porifera and Cnidaria 
representing 60% of the species accessed.4 Given our human-centric 
view, it is inevitable that the study of animal diversity has turned 
first to life forms that are visible to the naked eye and which are 
relatively easy to study; hence 95% of marine species investigated 
for biotechnological applications are animals and plants, with the 
remaining 5% bacteria. To date, a heavy focus on terrestrial systems 
characterizes the detailed study of the microbial world. However, 
recent interest in the marine environment through the work of the 
Sorcerer II Global Ocean Survey, or GOS (among many others), has 
begun to address this imbalance.5 A clear picture is beginning to 
emerge which shows that the oceans are a hotbed of microbial diver-
sity. This diversity has rarely been exploited for biotechnological gain 
(so-called blue biotechnology). Whilst past work has focused primar-
ily on the marine animal phyla, the vast majority of the microbial 
phyla have remained unexploited, despite preliminary work showing 
huge potential. Large-scale metagenomic surveys have revealed a 
diversity in metabolic function that has never been glimpsed previ-
ously. Upon analysis of their data, and despite being limited to sea 
surface microbes, the GOS team initially predicted twice as many 
novel proteins that were contained within public databases at the 
time.6 New protein families are still being discovered at a linear rate 
with the addition of new sequences, implying that we are still far 
from discovering all of the novel protein families found in nature. 
Indeed, this novelty is typified by the virus-derived sequences that 
have been discovered in the marine environment.7 Furthermore, the 
abundance of marine viruses (whose existence has only been known 
since the 1970s) is, quite simply, breathtaking: 1030 viruses inhabit 
the oceans (if lined up end-to-end, they would stretch approximately 
10 million light years) and are responsible for 1023 infections every 
second.8,9 Previously regarded as mere selfish bags of genes, the role 
of viruses in manipulating key metabolic processes (and hence their 
biotechnological potential) is now difficult to ignore.9,10
There is a growing recognition of the ocean’s biotechnological 
potential, with the global market currently estimated at US$2.4 
billion and with annual growth predicted at 10%. The European 
Commission describes it as “one of the most exciting technology 
sectors”, and the Institute of Marine Engineering, Science, and 
Technology (IMarEST) describes the sea as a “biotechnological fron-
tier waiting to be explored” with “potential for marine biotechnologi-
cal products to be used as anticancer agents, for bulk chemicals such 
as adhesives, for feed additives for aquaculture, and for remediation 
of environmental damage”.11 Current applications for high-value 
marine-derived products exist in many markets including antifou-
lants, biofilm inhibitors, bioremediation, high- and low-temperature-
tolerant enzymes with unique activities, human and animal tissue 
repair, nutraceuticals, and personal care products. As an example of 
a unique biomimetic product, the coupling of two natural adhesion 
structures, the gecko toe-pad and mussel byssus threads, has led to 
the water-resistant reversible adhesive “geckel”.12 In terms of bulk 
products, macroalgae are harvested for alginates and agar, and the 
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potential of microalgae has now been investigated for large-scale 
production of polyunsaturated fatty acids (PUFAs) for food and feed 
additives and biofuels. Since primary productivity of microalgae is 
high and they do not compete for agricultural land, they are proposed 
as the most promising source of oils for biofuels. Questions that 
remain are which species to use to obtain the maximum growth rates 
and oil content (and, hence, maximum yield) and how to efficiently 
convert the biomass to liquid fuel.
Several other large-scale opportunities present themselves for 
marine biotechnological applications. The recent banning of antibi-
otics in animal feed in the EU has led to the investigation of algal 
extracts as prebiotics with promising results.13 A worldwide ban 
on tin-based antifoulants for shipping is leading to the search for 
environment-friendly alternatives, from natural antifoulants derived 
from marine organisms incorporated in paints to the development of 
nanostructured materials mimicking mollusc shells with low adhesion 
properties.14 An oral vaccine approach has been developed, based on 
a genetically modified microalga (Chlamydomonas reinhardtii), which 
might be used commercially for control of various bacterial and viral 
diseases of fish and shellfish in aquaculture.15
As a final example, there is a need for a sustainable supply of PUFAs 
for human nutrition and aquaculture feed, calling for further devel-
opment of culture conditions for species rich in these essential nutri-
ents. Current supply is met by growing the microalga Cryptecodinium 
cohnii, and docosahexaenoic acid and arachidonic acid from this 
source have been approved by the US Food and Drug Administration 
for use in infant formula (Enfamil®; Mead Johnson Nutritionals; 
Paramus, New Jersey, USA [subsidiary of Bristol Myers Squibb]; and 
Martek Biosciences; Columbia, Maryland, USA). Well-known but 
smaller-scale applications exist in the life sciences and include the 
use of green fluorescent protein from the jellyfish Aequoria victoria 
to visualize intracellular processes, and proteins from the horseshoe 
crab Limulus polyphemus for immunohistochemistry.
Barriers to exploitation
The marine environment can clearly offer a great deal to the indus-
trial biotechnology community, yet there are a number of challenges 
which must be addressed if it is to realize its full potential. In brief 
these are: access (physical/legal); sustainable supply; greater under-
standing of marine species; molecular methods applicable to marine 
species; creation of integrated facilities; and policy initiatives to boost 
economic development based on the uptake of marine biotechnology 
by industry.
ACCESS: Physical
Very few facilities worldwide have the ability to access the deep 
ocean, whose average depth of 4000 m presents substantial engineer-
ing challenges. There is currently no submersible worldwide that can 
access the deepest point on the globe, Challenger Deep in the Mariana 
Trench (–10,911 m), after the loss in 2003 of the Japanese submers-
ible Kaiko operated by Japan Agency for Marine-Earth Science and 
Technology, or JAMSTEC. The last exploration of Challenger Deep 
by Kaiko was in 1998, and no manned submersible has visited since 
Walsh and Piccard’s expedition in the bathyscaphe Trieste in 1960. 
The recent news that Woods Hole Oceanographic Institution reached 
Challenger Deep using the US$8 million remotely operated, unmanned 
submersible, Nereus, in May 2009 is therefore to be applauded.
Access to deep sea hydrothermal vents with extreme temperatures 
or to the sea beneath polar ice presents even greater difficulties. 
Access to deep sediment cores is available via the International Ocean 
Drilling Program, using the Japanese vessel Chikyu,16 most of whose 
time is dedicated to geological and oceanographic research; but a 
recent study using cores from this program show that microbial life 
exists deep under the ocean’s floor.17 The greatest “frontier challenge” 
for humankind is perhaps not the repeat of manned lunar missions, 
but exploration of the most inaccessible reaches of our own planet. 
Many oceanographic institutions worldwide have the ability to collect 
using submersibles, but the available time for these is oversubscribed, 
and these facilities may be difficult to access and/or prohibitively 
expensive for start-up biotechnology companies. Infrastructure and 
engineering development is therefore necessary to provide inexpen-
sive and frequent access to the deep oceans, hydrothermal vents, 
and underneath polar ice for academic and applied purposes. Several 
initiatives worldwide are addressing this problem and to this end the 
UK’s National Subsea Research Institute is being located in Aberdeen 
to meet both the oil industry’s need for remotely operated underwater 
vehicle (ROV) development and research use by OceanLab, a facility 
for long-term monitoring of deep sea environments.
ACCESS: Legal 
The second access issue concerns the legal status of samples 
obtained from seas outside of national jurisdiction. In territorial 
waters access to genetic resources is covered adequately by the 
Convention on Biodiversity, and it is in these waters that most 
bioprospecting and biodiscovery takes place. With increased access 
to the deep oceans, the issue of collections in international waters 
becomes a legal issue.
Access to seafloor samples for marine scientific research is gov-
erned by the International Seabed Authority under the United Nations 
Convention on Laws of the Sea (UNCLOS).18 This convention predates 
the realization of the value of marine biodiscovery, and hence does 
not cover it adequately. The convention states that access to seafloor 
is for “peaceful uses of the seas and oceans, the equitable and efficient 
utilization of their resources, the conservation of their living resources, 
and the study, protection, and preservation of the marine environment”. 
In effect the ocean’s resources are the “common heritage of mankind”: 
UNCLOS states that no state shall claim sovereignty over any part of 
the Area (the Area being defined as the international seabed and ocean 
floor) or its resources, but no specific reference is given to marine 
genetic resources. Exploiting these is indeed an arm’s-length activ-
ity compared with the direct mining of minerals and metal ores from 
the seabed which the original drafters envisaged. Freedom to conduct 
marine scientific research requires sharing of results, which is not imme-
diately compatible with intellectual property rights, yet the requirement 
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for equitable sharing of financial and other economic benefits derived 
from this research suggests that someone has to “own”, manage, and 
disburse the benefits. An increased interest in accessing marine genetic 
resources from the deep ocean for biotechnological application by 
industry requires a rapid resolution of these incompatibilities and is a 
fascinating challenge for international property rights and equitable 
management policies.
SUSTAINABLE SUPPLY
The main barrier to efficient exploitation of marine resources in 
situ for biotechnological applications is realizing a sustainable sup-
ply. Many routes can be chosen and each may be applicable under 
different circumstances. Natural harvest is most often used for bulk 
products such as alginates from macroalgae. Collection of marine 
invertebrates for high value products (e.g., enzymes and pharmaceu-
ticals) is difficult due to low yields, seasonality, and variability and 
can only be achieved for small-scale trials. On the other hand, fishing 
and aquaculture wastes can offer an abundant source of high-value 
products. One such use arose from the extraction of cold alkaline 
phosphatase, used for dephosphorylation of DNA and proteins, 
from thawing shrimp waste (Biotec Pharmacon; Tromsø, Norway). 
Managed large-scale culture has been successful for the produc-
tion of PUFAs (Crypthecodinium cohnii) and carotenoids (Dunaliella 
salina, Haematococcus pluvialis), but has been shown to be uneco-
nomical for the production of potential pharmaceuticals from marine 
invertebrates. The cancer therapeutic trabectidin (now approved as 
Yondelis; Pharmamar; Madrid, 
Spain) was initially obtained 
from the ascidian (seasquirt) 
Ecteinascidia turbinata, ini-
tially by a US-based, now-de-
funct company Calbiomarine, 
and later transferred to the 
Mediterranean. This early 
stage production was estimat-
ed to cost $2,900–7,000 per 
gram of pharmaceutical mate-
rial and hence an alternative 
was necessary for commercial 
production. In this case, which 
is perhaps a model for many 
marine-derived complex bio-
actives, a Pseudomonas strain 
was found which was eas-
ily grown in bioreactors and 
produced a precursor of tra-
bectidin, which could then be 
chemically altered to generate 
the active product and ana-
logues.19 The culture of marine 
microorganisms can now be 
achieved, the main challenge 
being the corrosive nature of seawater on stainless steel culture 
vessels, but this can be addressed through the use of appropriate 
cleaning protocols. Nereus Pharmaceuticals (La Jolla, California) was 
able to obtain an initial batch of 1 kg of pharmaceutical-grade salino-
sporamide (NPI-0052) for use in clinical trials, through fermentation 
in saline media of the obligate halophile Salinispora tropica by its 
subcontractor IRL-Biopharm (Lower Hutt, New Zealand).
Sustainable supply is a particular challenge for production of 
promising bioactives from sponges and other invertebrates, where 
the molecules may actually be produced by microbial symbionts, 
many of which are in an obligate association with their hosts. The 
initial example of success in culturing sponge-derived bacteria to 
produce a high-value compound was the production of the anti-
parasitic manzamine alkaloids by a Micromonospora species isolated 
from an Indonesian Petrosiidae sponge, which was able to grow 
independent of its host.20 In cases where the invertebrate is respon-
sible for production of the compound of interest, tissue culture may 
offer an answer. Tissue culture of invertebrates is in its infancy due 
to our limited knowledge of marine invertebrate physiology, but is 
being developed at a number of institutes, with moderate success.21 
Potentially the most promising route is the use of recombinant DNA 
techniques to achieve expression of genes from difficult-to-grow 
or unculturable marine organisms in heterologous, easily cultured, 
microbial hosts. This, however, is easier said than done. Heterologous 
expression systems have been developed for a range of terrestrial 
organisms including Escherichia coli (bacteria), yeast (eukaryotic), 
Marine invertebrate biodiversity: six different phyla: (a) Chordata (seasquirt); (b) Echinodermata (seastar);
(c) Coelenterata (soft coral); (d) Mollusca (sea slug); (e) Porifera (sponge); (f) Bryozoa (sea moss)
FEATURE COMMENTARY
80  INDUSTRIAL BIOTECHNOLOGY  SUMMER 2009
Arabidopsis (plant), the fruit fly Drosophila (invertebrate), and the 
mouse (mammal) systems. A system has also been developed for 
the microalga Chlamydomonas. Put simply, the closer in origin the 
recombinant DNA is to the host expression system, the more likely 
it is to be productively and accurately processed, so that the desired 
protein is expressed (or even overexpressed), folded, and subjected 
to the correct posttranslational modifications necessary for activity. 
For example, for marine-derived genes, notable success has been 
obtained by the authors in expressing cyanobacterial genes in E. coli, 
and algal virus genes in Saccharomyces cerevisiae.22,23 However, the 
sheer diversity of organisms from the marine environment, combined 
with their associated environments, has proven to be an enormous 
barrier to the heterologous expression of the majority of marine-
derived genes. Despite the limited success to date, the vast majority 
of bacterial genes from the marine environment are unable to be 
expressed correctly in E. coli. Thus, perhaps the greatest barrier of 
all in marine biotechnology is the dearth of appropriate heterologous 
expression systems suitable for genomic material of marine origin.
UNDERSTANDING MARINE ORGANISMS 
& THE DEVELOPMENT OF MOLECULAR TOOLS 
E. coli is the workhorse of modern molecular biology and the 
best-studied system on the planet.24 Despite this intense study since 
its first isolation in 1885, almost 40% of its genes were classified 
as of unknown function when the genome was sequenced.25,26 Few 
model systems can compete with E. coli with regard to the amount of 
biochemical understanding we have; yet, as E. coli shows, complete 
understanding is not necessary to turn an organism into a useful and 
versatile tool. With increased understanding of any model system 
comes the ability to develop and modify tools to manipulate it.
Compared with our perception of the vast diversity of marine spe-
cies, our specific understanding of their genetics, physiology, and 
ecology is tiny. What is needed is a concerted approach to gather 
basic information (such as genome size, metabolic potential, growth 
conditions) on all marine animal, plant, and microbial phyla. At the 
very least, one or more candidates per phylum need to be identi-
fied for development as model heterologous expression vehicles 
for their respective phyla. We therefore urge the sequencing of the 
entire genomes of marine representatives of every animal, plant, and 
microbial phylum, as well as viruses. Again, this is easier said than 
done. The vast majority of marine microbes have resisted all efforts 
at culturing under laboratory conditions. Furthermore, many marine 
species live in essential symbiotic relationships, and all partners will 
need to be sequenced to understand the symbiosis and the factors 
that govern them (as well as the complementary or shared genetics). 
Viruses complicate things further since they require a suitable host 
for propagation. 
Metagenomic approaches have circumvented the requirement for 
laboratory culture in order to obtain enough genomic material, but 
have their limitations.27-29 By definition, metagenomic sequences 
are obtained from mixed populations, and the precise source of the 
genomic material is unknown unless suitable markers are associated 
with the sequences.30 Material from common organisms will swamp 
sequences from much rarer ones. The larger the genomic frag-
ment, the greater the chance of finding a suitable marker associated 
with the sequence, and originally this was quite common with the 
large insert BACs libraries that were used for the first metagenomic 
sequencing projects.31
The recent trend towards pyrosequencing fragmented genomic 
material directly (even with the increased sequencing read lengths 
of 450–500 bases) massively reduces the chance of finding mark-
ers and is heavily reliant upon the correct assembly of millions of 
small fragments. This is further complicated by viruses, which have 
no common marker and whose genomic material is among the most 
diverse on the planet.27 Indeed, the sequences of many giant marine 
viruses contain regions with stretches of genes which have no simi-
larity to any existing database entries.32 This is by no means a rare 
occurrence in the field of marine genomics. Accurate annotation 
of marine-origin genes will require additional effort at the bench 
and in the development of bioinformatic tools. To achieve cloning, 
expression and functional characterization of marine genes and their 
associated products will require the development of the heterologous 
expression systems mentioned previously. The recently announced 
Genome Analysis Facility at the John Innes Centre in Norwich, 
UK, will provide sequencing capabilities for nonpathogenic species, 
including marine invertebrates, bacteria, and viruses and may make 
a significant impact in helping this situation.
INTEGRATED FACILITIES 
There is a need for scientists from different disciplines to be co-
located to achieve the most effective generation of new ideas for 
marine biotechnology. Many such centers exist in marine institutions 
and laboratories worldwide but there are few that truly embrace all 
aspects needed to be successful. In the USA, the Scripps Institution 
of Oceanography, Harbor Branch Oceanographic Institution, and the 
Centre of Marine Biotechnology at the University of Maryland offer 
good examples. An excellent example of academic, industry, and gov-
ernment interaction in Europe is MabCent in Tromsø, Norway, which 
aims to derive high-value small molecules and novel enzymes from 
cold-adapted invertebrates and microorganisms. A large government 
grant has been matched by the University of Tromsø and by local 
companies that have been successful in commercializing marine-
derived biotechnology products such as the previously mentioned 
shrimp alkaline phosphatase. In the UK, the Centre of Excellence 
for Biocatalysis, Biotransformation, and Biocatalytic Manufacture 
(CoEBio3; University of Manchester) acts as an interface between 
academia and industry and uses Plymouth Marine Laboratory as 
a partner to access and exploit the marine environment. A more 
focused biodiscovery center is being created in Seoul, Korea (Center 
for Marine Drug Discovery), and a smaller facility is being built in 
Aberdeen, UK (Marine Biodiscovery Centre). From a commercial 
aspect, the European Centre for Marine Biotechnology in Oban, 
Scotland, provides an incubator unit for innovative marine biotech-
nology start-ups such as Aquapharm Biodiscovery and Glycomar. 
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Core facilities available to a number of investigators and companies 
also speed up innovation in blue biotechnology. The Centre for 
Process Innovation (Wilton, UK) makes bioreactors available for 
saline and non-saline fermentations for process parametrization as 
well as the associated downstream processing. This type of facility 
and expertise is otherwise not available to start-ups and academic 
groups to take a process from bench-scale to production scale. 
ACHIEVING THE RIGHT MIX
Making marine biotechnology effective for the generation of new 
ideas, processes, and products requires the bringing together of skills 
and equipment from a host of disciplines, including taxonomy (a 
dying art), marine invertebrate biology, marine microbiology, molec-
ular biology, genetics, chemistry, biochemistry and biomedicine — in 
addition to which many other disciplines should be included as pos-
sible end users (biomaterials, nutrition, etc). The daily interaction 
among these scientists, when adequately resourced and focused on a 
common goal, will create novelty in many fields (such as the example 
of geckel referred to previously).
Achieving this implies researcher-researcher interactions as well as 
researcher-industry communication. Nevertheless, a great deal of mis-
trust exists, and researchers may refrain from interacting with others 
for a variety of reasons. Perhaps they hope to claim a “larger share 
of the pie” once exploitation is achieved. Maybe they have suffered 
as a result of “stolen” ideas, authorship issues, and anonymous peer 
review, which leave a bitter taste even if they arise independently of 
financial considerations. The thought of having ideas of commercial 
relevance stolen is often too hard to bear for many researchers, who 
hold on to the dream that this time next year they will be million-
aires. Yet without the appropriate guidance, expertise, and industrial 
savvy it is common for even excellent ideas to end up going nowhere. 
Our view is that it is better 
to have a small percentage 
of something than 100% of 
nothing. The use of non-
disclosure agreements and 
material transfer agreements 
with data-back provisions for 
protecting intellectual prop-
erty at an early stage (thus 
allowing consultation with 
relevant industrial partners) 
can avoid many of these 
issues, but is quite often not 
considered.
In the UK, the develop-
ment of networks, either vir-
tual (such as the Bioscience 
Knowledge Transfer Network, 
or KTN) or based on a specific 
activity, such as CoEBIO3 
in which Plymouth Marine 
Laboratory is involved, have allowed productive face-to-face inter-
action between academic and industrial partners that can help break 
down the barriers between applied and commercial scientists to 
promote the exploitation of ideas—but this needs boosting. The UK’s 
Research Councils can have a role to play, as promoters and funders 
of the “sandpit” concept of developing grand-scale projects and pro-
grams of high-quality science with a specific goal. These activities are 
not frequent enough, and industry will benefit from taking more of 
a lead in promoting these interactions if they are to exploit marine 
bioresources effectively.
We can see the need for this most clearly in the pharmaceutical 
sector. Small molecules derived from terrestrial species are the origin 
of more than half of all currently used pharmaceuticals and of 75% 
of cancer therapeutics and anti-infective agents.33 Similarly, most 
biotechnological products on the market today are derived from ter-
restrial species. The pharmaceutical industry now seems stuck, after 
a decade and a half of combinatorial chemistry based on structure-
activity relationships, in a mind-set that too often sees the second, 
third, and following companies in a market “playing little tunes on 
the structures of the first company”.
To understand why the astonishing biodiversity to be found in 
the seas has not been fully exploited, we have to look at how large 
pharmaceutical companies regard marine sources for novel products 
and processes. Some of the answer rests in the technical difficulties 
described earlier, but much is to do with attitude. Despite the obvi-
ous opportunities, the mainstream pharmaceutical industry (“Big 
Pharma”) has little in-house experience in dealing with marine biore-
sources, and hence this work is driven by academic centers and start-
up companies. In the pharmaceutical arena Pharmamar has been 
among the most successful, with a large pipeline of marine-derived 
cancer chemotherapeutics. The smaller US-based company Nereus 
Marine viruses can only been visualized by electron microscopy. Left, a large double-stranded DNA virus can be 
seen attached to the outer membrane of an Ostreococcus cell (the smallest living free eukaryote, with an aver-
age size of approximately 1 micron). Right, a group of similar-sized, uncharacterized Micromonas viruses.
Images by Karen Weynberg of Plymouth Marine Laboratory.
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Pharmaceuticals (San Diego, California) has successfully and rapidly 
translated academic research on marine bacteria into clinical trials.
For non-pharmaceutical applications such as nutraceuticals, 
Martek leads the way, but smaller companies with broad portfolios 
such as Aquapharm Biodiscovery are also making a contribution in 
this area. Other companies have accepted marine bioresources as one 
of their routes to discovery of novel enzymes (Ingenza; Edinburgh, 
Scotland, UK) or cosmetic ingredients (Croda International; Goole, 
UK). Because of this, the risk for large companies can perhaps be 
mitigated by collaboration with, and, potentially, acquisition of, these 
higher-risk companies for their respective intellectual property port-
folios. This model is already common for the pharmaceutical industry 
and is likely to become more common in the area of marine-based 
industrial biotechnology.
The next generation of marine scientists needs to be trained for 
the demands of the 21st century. In the current climate for academic 
research it is now rarely enough just to perform “blue skies” research; 
it is becoming increasingly common to have to justify end points 
and identify the potential exploitation opportunities associated with 
research projects. However, many marine scientists, attracted to the 
field for their love of the ocean, have not received appropriate training 
in biotechnological awareness. The movement of scientists from other 
research domains into the marine sector might aid the spread of this 
attitude, but the problem also needs to be addressed at the grassroots 
level. Those courses and modules in applied marine research that are 
available at many universities are often optional and certainly not 
viewed as essential requirements of marine science courses.
The need for appropriate training to derive maximum value from 
natural resources for small-molecule and biotechnological applica-
tions has been recognized, and forms the core of a report on this 
topic released in the UK in 2006.34 This report notes that start-up 
companies in the UK struggle to recruit trained personnel; it also 
recommends that companies work with universities to address the 
skills gap and that funding be increased for interdisciplinary science 
to result in a new generation of scientists comfortable in applying 
techniques from various fields to solve complex problems. One way 
this has already been implemented in the UK is in the “discipline-
hopping” fellowships, which allow postdoctoral scientists or academ-
ics to spend time learning another subject, to apply their knowledge 
in this new field as well as bring back the newly learned skills and 
techniques to their own research. One of the authors of this manu-
script (Marcel Jaspars) is the recipient of such a fellowship, funded 
by the UK’s Biotechnology and Biological Sciences Research Council, 
to learn molecular genetics techniques to apply to the field of marine 
natural product chemistry.
POLICY
Many of the challenges outlined above need a change in
policy — economic, political or legal — to create a coherent drive to 
investigate the oceans and develop their biotechnological potential. 
It is likely, however, that opposition, even from within the marine 
sector, will greet any intention to shift policy significantly. It is none-
theless imperative that there be a shift away from the “buzz area” in 
current marine research, namely, climate change. It cannot be denied 
that climate change is of major concern in the present day, yet we 
need a balance with biotechnology as well as the other research areas 
referred to above.
This is being achieved in some countries, in different ways. 
Large-scale facility funding may be very effective; the largest initia-
tive using this is the Centre for Marine Natural Products and Drug 
Discovery in Seoul, Korea, which represents a 10-year program and 
has an allocated budget of over US$70 million, to develop medicines 
for metabolic and immune disorders and infectious diseases. MabCent 
in Tromsø, Norway, brings together and builds on existing expertise 
in marine science and blue biotech SMEs and has funding assigned to 
it of $25M over 7 years. National programs exist in Ireland (Beaufort 
Programme) and Germany (Biomarin), and targeted platform or proj-
ect funding for marine biotechnology research exists in a number of 
countries (Denmark and USA).
Making industry aware of new biotechniques and sources of inno-
vation can be powerful, provided these are relevant to their products 
and processes and important for their future survival. In the UK, link-
ages between industry, academia, and government are fostered as a 
matter of policy through the Knowledge Transfer Networks, funded 
by the Technology Strategy Board. The main aim of these networks 
is to accelerate the rate of technology uptake by UK businesses to 
improve innovation performance. The Bioscience Knowledge Transfer 
Network brings to reality slogans such as “Nature’s solutions to ben-
efit Society” and “Use today’s sunlight not yesterday’s”, by providing 
unique connections among white (industrial), green (plant-based), 
and blue sectors of industrial biotechnology. It acts as a conduit 
for biobased technology business to engage with government, other 
businesses, and the research community including major funders and 
trade organizations.
All early indicators suggest this is leading to an increased uptake 
of biotechnology of all “colors” by industry in the UK. The Bioscience 
KTN has had a particular impact in helping raise the profile of blue 
biotechnology in UK and Europe and is currently being assessed as a 
model for application in Canada.
Conclusions
To realize the potential that the oceans offer in terms of new prod-
ucts and processes requires the concerted effort of many parties. What 
is urgently needed is the coordination of marine sciences, including 
marine biotechnology, and the adequate funding of interdisciplinary 
initiatives. Effective academic–industrial collaboration is essential to 
bring any novel marine biotechnological outputs to the market. This 
will require the training of scientists in relevant disciplines and a 
new generation of interdisciplinary scientists who feel comfortable in 
applying tools from diverse fields to solve unique problems posed by 
the marine environment. We also need to increase our knowledge of 
the fundamental biology and ecology of marine species, which can 
only be gained by intensive research and the generation of marine-
relevant tools together with integrated facilities.
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